News DexCom, Inc.

Stocks

DXCM

US2521311074

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 11:24:51 2026-06-24 EDT			5-day change	1st Jan Change
69.88 ^USD	+1.39%		-2.23%	+4.93%

06-23	Deutsche Bank Initiates Coverage on DexCom With Buy Rating, $86 Price Target	MT
06-16	AI Can Play 'Significant' Role in Tech for Managing Diabetes, Says David Roman	MT

All News

Mentions Relevance

06-23	Dexcom Further Advances Vision of Glucose Biosensing for All	BU
06-23	Deutsche Bank Initiates Coverage on DexCom With Buy Rating, $86 Price Target	MT
06-16	AI Can Play 'Significant' Role in Tech for Managing Diabetes, Says David Roman	MT
06-15	Piper Sandler Adjusts Price Target on DexCom to $88 From $75, Maintains Overweight Rating	MT
06-12	Dexcom Inc Clears First Over-The-Counter Continuous Glucose Monitor For Children	CI
06-12	FDA clears first over-the-counter glucose monitor for children	RE
06-11	Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction	RE
06-10	TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating	MT
06-09	Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating	MT
06-08	Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating	MT
06-06	Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin	BU
06-06	Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study	RE
06-06	DexCom, Inc. Announces Results From CONNECT Randomized Controlled Trial Demonstrating Use Of Dexcom G7 Leads To Clinically And Statistically Significant Reduction In A1C And Improvement In Glucose Control Among People With Type 2 Diabetes Not Using Insulin	CI
06-05	Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating	MT
06-04	Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026	BU
06-04	DexCom Presents Results from The CONNECT Randomized Control Trial, Launches Reimagined Stelo Ap	CI
06-02	Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience	BU
05-28	Citigroup Adjusts Price Target on DexCom to $84 From $79, Maintains Buy Rating	MT
05-27	Signos, Inc announced that it has received $20 million in funding from GV Management Company, LLC, DexCom, Inc., Blue Cross and Blue Shield of Alabama	CI
05-27	Signos raises $20 million investment from Google Ventures, Dexcom, Blue Cross Blue Shield of Alabama	RE
05-27	Goldman Sachs Adjusts Price Target on DexCom to $85 From $80, Maintains Buy Rating	MT
05-26	Dexcom warns patients as stolen glucose sensors hit the market	RE
05-26	DexCom Reports Theft of Scrapped G7 Glucose Monitor Sensors	MT
05-26	Dexcom uncovers theft of scrapped product, notifies potentially impacted users	RE
05-26	Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users	BU